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The kappa‑opioid system (KOP) is the key in drug abuse. Of all the compounds isolated from Salvia divinorum (S. divinorum), salvinorin‑A 
(Sal‑A) is predominant. Further, Sal‑A is the only compound within S. divinorum which is reported to have psychoactive properties as 
a powerful kappa‑opioid receptor (KOPr) agonist. Based on the key role of the KOP system in the consumption of drugs, S. divinorum 
extract (SDE) and Sal‑A may modify the alcohol intake in Wistar rats. Assessing voluntary alcohol intake as a  drug consummatory 
behavior, food intake as natural reward behavior and tonic immobility as indicative of anxiety‑like behavior, the present study sought to 
identify the role of both SDE and Sal‑A in the Wistar rat model. Forty‑eight adult male rats were randomly divided into six groups: control, 
alcohol naive and vehicle, alcohol‑naive and SDE, alcohol‑naive and Sal‑A, alcohol‑consumption and vehicle, alcohol‑consumption and 
SDE, and alcohol‑consumption and Sal‑A. Alcohol and food intake were assessed for two weeks. In the middle of these two weeks, 
vehicle, SDE (containing ~1 mg/kg of Sal‑A) or Sal‑A was injected intraperitoneally once a day for a week. Tonic immobility testing was 
performed once. The administration of SDE produced a significant increase in voluntary alcohol intake especially in rats with a history 
of forced alcohol consumption from a  juvenile age, Sal‑A elicited an increase in alcohol intake in animals with or without previous 
alcohol exposure, SDE and Sal‑A prolonged the tonic immobility duration and decreased food intake. In conclusion, S. divinorum or Sal‑A 
stimulated alcohol consumption in rats with a history of alcohol intake and independent of previous exposure respectively, also SDE or 
Sal‑A elicited an anorexigenic effect, and increased tonic immobility as indicative of anxious‑like behavior.
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INTRODUCTION
Salvia divinorum (S. divinorum) (Lamiaceae family; 
formerly Labiatae) contains diterpenes such as salvi-
norin A and B, as well as additional diterpenoids, 
divinatorines (A-F), salvidivines (A-D), salvinicins (A 
and B) and nine additional salvinorins (C-J) (Keasling 
and Zjawiony, 2016). Salvinorin A (Sal-A) is the only 
known psychoactive/hallucinogenic constituent of S. 
divinorum. Structurally, Sal-A is a unique furanolac-
tone neoclerodane diterpene which acts as a potent 
non-nitrogenous selective kappa-opioid receptor 
(KOPr) agonist (Roth et al., 2002; Willmore-Fordham 
et al., 2007). In contrast to LSD, psilocybin, dimeth-
yltryptamine, and mescaline, Sal-A has no known 
activity at the classical hallucinogen drug-receptor 
Received 23 March 2020, accepted 13 January 2021
RESEARCH PAPER
Acta Neurobiol Exp 2021, 81
DOI: 10.21307/ane‑2021‑005
: 34–42
S. div. increases alcohol/anxiety and decreases food intakeActa Neurobiol Exp 2021, 81
serotonergic system (5-HT2A) (Roth et al., 2002; Pris-
inzano, 2005; Johnson et al., 2011). Due to its powerful 
hallucinogenic effects, S. divinorum is often co-con-
sumed (smoking) with alcohol. Sal-A isolated from S. 
divinorum leaves produced a unique profile of subjec-
tive effects in humans, similar to other classic hallu-
cinogens (Johnson et al., 2011). When smoked, a sin-
gle dose of Sal-A (200-500 µg) results in strong, yet 
brief (5-10 min), hallucinogenic effects and a change 
in perception (Siebert, 1994). 
The toxicity of S. divinorum or Sal-A is relatively low. 
For instance, this observation is highlighted by the dos-
es at which humans are commonly exposed to during 
healing/ritual practices by the Mazateca ethnic group 
in Oaxaca, Mexico (Mowry et al., 2003). Further, it is 
well known that S. divinorum is traditionally used for 
divination practices, spiritual rituals, and training of 
medical practitioners (Valdés et al., 1983). More recent-
ly S. divinorum leaves are smoked on recreational/hal-
lucinogenic use worldwide (Casselman and Heinrich, 
2011). Internet vendors and “head shops” sell S. divi-
norum plants, dried leaves, leaf extracts with increased 
Sal-A concentrations for smoking, or as tinctures for 
oral administration (Johnson et al., 2011). 
Clinically, there is increasing evidence that links 
the action of the endogenous opioid neuropeptide, 
dynorphin, in modulating mood and increasing the 
reward effects of abused drugs (Bruchas et al., 2010). 
It has been hypothesized that the kappa-opioid sys-
tem (KOP) largely modulates drug consumption, in or-
der of the number of publications: cocaine, alcohol, 
opioids and nicotine and cannabinoids to a lesser ex-
tent (Wee and Koob, 2010). Previous studies have pro-
vided evidence of an anti-addictive effect resulting 
from KOPr stimulation (Prisinzano et al., 2005), while 
others have found that KOPr antagonists may reverse 
motivational aspects of dependence (Wee and Koob, 
2010). Furthermore, in animal models of drug rein-
statement, KOPr stimulation can induce a relapse via 
a stress-like mechanism (Wee and Koob, 2010). Previ-
ous animal studies suggest that manipulations which 
reduce the activity of the KOP system may be effec-
tive in the treatment of depression and drug addiction 
(Shippenberg, 2009). 
Additionally, the activity of kappa agonists, includ-
ing the highly selective KOPr agonist U50, 488H, stim-
ulates food consumption in rats (Cooper et al., 1985). 
Further, food ingestion was increased after treating 
animals with different peptide chains of dynorphin 
(1-17, 1-10, 1-11, 1-13 and 3-13) the endogenous KOPr 
ligand. However, in rhesus monkeys, the intramuscular 
administration of bremazocine (a µ and KOPr agonist at 
0.00032-, 0.001-, and 0.0025-mg/kg i.m.) under a fixed 
ratio schedule reduced the response to cocaine, etha-
nol, phencyclidine, saccharin, and food in a dose-de-
pendent manner (Crosgrove and Carroll, 2002). 
The activation of the dynorphin/KOP system has also 
been shown to be necessary for stress-induced behav-
ioral responses in animal models of anxiety, depression, 
and drug-seeking behaviors (Bruchas et al., 2010). The 
cataleptic immobility, or catalepsy, can be defined as 
a failure to correct externally imposed “awkward pos-
tures”, whereas tonic immobility (TI) is a reversible state 
of immobility which can be caused by a wide range of ex-
ternal stimuli. In the laboratory, TI involves the physical 
restraint and release of the animal, generally in a supine 
position. Additionally, TI is used as a proxy for innate 
passive defensive terminal behavior in several species 
and is characterized by a profound, yet temporary, state 
of motor inhibition which is often assessed as the laten-
cy time immediately before of the righting reflex in rats 
(Miranda-Páez et al., 2016). TI can be considered as an 
index of an anxiety-like state (Vázquez-León et al, 2017). 
In an exploratory environment where cues were intro-
duced to elicit a variety of spontaneous reactive behav-
iors (e.g. righting reflex, response to pencil-pokes, and 
reaction to food stimuli), 0.1 and 0.3 mg/kg doses of Sal-A 
produced no-effects in female rats. However, higher dos-
es (1.0 mg/kg, 3.0 mg/kg and 5.6 mg/kg) produced mo-
tor incoordination during the last 15 min of observation 
as well as dose-dependent catalepsy at times proximal 
to i.p. drug administration (Willmore-Fordham et al., 
2007). Moreover, KOPr activation is associated with de-
pression-like behaviors, characterized by increased im-
mobility in the forced swim test (FST) in rats (Carlezon 
et al., 2006), while KOPr antagonists have been shown 
to improve this immobility through anxiolytic activity 
(Knoll et al., 2007). However, some reports suggest that 
Sal-A produces both anxiolytic and antidepressant-like 
effects in rodents (Braida et al., 2009). 
Due to the heterogeneity of the findings regarding 
the behavioral profile of S. divinorum and Sal-A admin-
istration, the present study aimed to provide clear in-
sights into the effects of S. divinorum extract (SDE) con-
taining Sal-A as the main pharmacological active con-
stituent, and Sal-A itself, on alcohol and food intake as 
well as tonic immobility. To our knowledge, this is the 
first evaluation of the influence exerted by SDE or Sal-A 
injection on voluntary alcohol consumption, food in-
take, and TI in rats.
METHODS 
Animals
Male Wistar rats (21 days old) (N=48) were ob-
tained from the vivarium of the Escuela Nacional de 
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Ciencias Biológicas of the Instituto Politécnico Na-
cional (Mexico). Animals were randomly divided into 
six groups (n=8) as follows: control, with standard lab 
chow diet and tap water, and injected vehicle (AN-
VEH), alcohol-naive, with standard lab chow diet and 
tap water, plus S. divinorum extract injection (ANSDE), 
alcohol-naive, with standard lab chow diet and tap 
water, plus Sal-A injection (ANSALA), forced alcohol 
intake plus vehicle injection (ACVEH), forced alcohol 
intake and SDE injection (ACSDE), and forced alcohol 
intake and Sal-A injection (ACSALA). All injections 
were administered i.p. The rats were housed four per 
cage (32.5 × 20 × 40 cm), kept on a 12/12-h light/dark 
cycle (lights on at 7:00 a.m.) in a room with controlled 
temperature (20-22°C) and humidity (45-55%), and, in 
the case of the three alcohol-naive groups, provided 
ad libitum access to food and tap water. The alcohol 
consumption groups (ACVEH, ACSDE and ACSALA) 
were provided with an ethanol solution (6% v/v) in-
stead of tap water from the post-natal day (PND) 21 
to 67 (first forced alcohol intake period), followed by 
a one week with tap water as the only liquid in the 
diet (first imposed alcohol withdrawal period). A sec-
ond forced alcohol intake period (10% ethanol solu-
tion v/v) was carried out at PND 76–106, followed by 
a second imposed alcohol withdrawal period at PND 
107–114 (as previous treatment or condition). The ex-
perimental design was based on Mendoza-Ruiz et al. 
(2018) (Fig. 1).
Body weights were measured twice a week from 
PND 21 to 67 and from PND 76 to 106, and daily during 
the voluntary alcohol consumption evaluation peri-
od. The experimental protocol of the study was car-
ried out in accordance with procedures established 
by the NIH in the Guide for the Care and Use of Lab-
oratory Animals (NIH Publications No. 8023, revised 
1978), and the Mexican Guidelines for Animal Care 
(NOM-062-ZOO-1999). 
Drugs
The Salvia divinorum extract
The leaves of S. divinorum were purchased from Sal-
via Mx Smartshop (México City – voucher no. 3158). The 
plant used was identified by Dafné Córdova-Maqueda 
(Palynology Laboratory, Botany Department, Escuela 
Nacional de Ciencias Biológicas, México City). SDE was 
obtained by means of a simple maceration using meth-
anol as solvent. 40 g of the dry leaf were weighed, the 
sample was pulverized with a mortar for about 10 to 
15 min and it was transferred to a 100 mL flask, 80 mL 
of methanol was added and left to stand for a 3-day 
period with an occasional stirring such was eliminated 
as a first decanted high in chlorophyll. 80 mL of meth-
anol was added once again and left in maceration for 
a week. The same procedure was repeated from the 
methanol addition; the product was collected from 
the 2 washes before it was then filtered. Following fil-
tration, the solvent was removed by means of distilla-
tion under reduced pressure using a rotary evapora-
tor (Prendo™, Model 1750, Puebla, Mexico) to obtain 
0.528 g of the crude extract. 250 mg of the crude extract 
was dissolved. Two independent chemical analyses of 
the SDE were conducted. First, a qualitative analysis 
of the components of the SDE was carried out by Miss 
Maricarmen Morales and Dr. Jorge Mendoza, both from 
Escuela Nacional de Ciencias Biológicas at Nanoscienc-
es Center of the IPN, México City, using nuclear mag-
netic resonance proton spectroscopy (NMR1H) using 
autoflexTOF/TOF and D:\Methods\flexControlMeth-
ods\RP_700-3500_Da_MBGP.par. Second, SDE was eval-
uated by mass spectrometry coupled to high-perfor-
mance liquid chromatography (MS-HPLC), salvinorin A 
(C23H28O8; Molecular Weight: 432.5 g/mol) constituted 
4% of the methanolic extract (Method: MassLynx 4.1 
SCN810; Instrument: XEVO-TQMS#VBA605) with ref-
Fig. 1. Experimental design. AN, alcohol naive; BW, body weight; FAC, forced alcohol consumption; PND, postnatal day; SALA, Salvinorin A; SDE, Salvia 
divinorum extract; TI, tonic immobility; VEH, vehicle.
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erence to salvinorin A (Cayman chemical®, Ann Arbor, 
Michigan, USA) [See supplemental materials]. Using 
these data, the approximate concentration of Sal-A 
from the SDE to be administered to the rats within 
this study was calculated to be 1 mg/kg body weight 
(BW). For the SDE, the vehicle (VEH) was DMSO (10%) 
and Tween 80 (10%) in sterile saline isotonic solution 
(Sufka et al., 2014). The SDE, or its respective vehicle, 
was injected via i.p. at a dose of 1 mL/kg, according to 
Sufka et al. (2014). 
Salvinorin A
Salvinorin A. IUPAC Name: methyl (2S,4aR,6aR,
7R,9S,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)-6a,10b-di-
methyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-ben-
zo[f]isochromene7-carboxylate. (Cayman chemical®, 
Ann Arbor, Michigan, USA), was dissolved in 10% DMSO 
and 10% Tween 80 in a sterile saline isotonic solution 
(Sufka et al., 2014). 1 mg/kg BW in a volume of 1 mL/kg 
was injected via i.p daily from days 7 to 14 of food and 
fluids consumption assessment.
Alcohol intake assessment
Voluntary ethanol consumption was measured for 
the rats kept in individual cages. Each rat had access 
to three standard glass tubes (70 mL, 25 × 200 mm) 
equipped with a glass mouthpiece containing a ter-
minal hole (diameter=1 mm) to allow for fluid intake 
by licking with a minimum of spillage. The glass tubes 
were mounted on the front of the cage and each was 
previously filled with a different solution: tap water, 
10% v/v ethanol-water, and 20% v/v ethanol-water. 
Ethanol solutions were freshly prepared from 96% 
ethyl alcohol (C2H5OH, Merck® Darmstadt, Germany). 
Both alcohol concentrations were chosen based on 
previous reports (Spanagel and Hölter, 1999; Mendo-
za-Ruiz et al., 2018). The positions of the three tubes 
were randomly rearranged daily to avoid position 
preference. Each assay tube was weighed to quanti-
fy the amount of alcohol consumed per solution. Al-
cohol ingestion was calculated in grams of absolute 
alcohol per kg of body weight (g/kg) daily at two pe-
riods: one week before and one week during vehicle, 
SDE or Sal-A injection (i.p.) once a day. 
Food intake assessment
Approximately 50 g of standard lab-chow food pel-
lets (Propecua™) were available in a stainless-steel con-
tainer at the front of the individual cage. The lab-chow 
pellets were replaced daily and located next to the three 
glass tubes. The food container was briefly removed and 
the food was weighed daily (during the two weeks of ex-
amination of voluntary alcohol consumption) to deter-
mine the quantity (g) eaten. The food intake measure-
ment for each rat was rectified for unavoidable spillage. 
Tonic immobility test 
On day-123 (15 min after the vehicle, SDE or Sal-A 
corresponding i.p. injection), animals were subjected 
once to the tonic immobility test by using two 5-cm 
rubber-tipped alligator clips, one clamped to the dorsal 
and the other to the ventral part of the neck. Each clip 
exerted 1300 g/cm2 of force on approximately 1 cm2 of 
neck skin. The animal was then inverted to a supine-lat-
eral position and gently maintained in this posture un-
til it stopped struggling (if applicable) and remained 
immobile. The duration of TI was measured from the 
time the experimenter’s hand was removed until the 
animal recovered the prone position (latency of right-
ing reflex) for a maximum of 180 s (Miranda-Páez et al., 
2016; Vázquez-León et al., 2017). Consumption of fluids 
and food measurement began at 19:00, while TI assess-
ment between 17:30 and 19:00. 
Statistical analyses
All data in the text and figures are expressed as 
the mean ± SEM. Alcohol and food intake were exam-
ined with a two-way analysis of variance for repeat-
ed measures (two-way RM-ANOVA), considering al-
cohol initiation procedure (alcohol-naive or alcohol 
forced groups), and injected drug (VEH, SDE or Sal-A), 
followed by a multiple comparison procedure (Stu-
dent-Newman-Keuls). The duration of tonic immobility 
was scrutinized with a non-parametric one-way ANOVA 
(Kruskal-Wallis test) followed by a multiple compari-
son procedure (Student-Newman-Keuls), therefore, the 
values represent the median as the measure of central 
tendency, and the lower (25%) and the upper (75%) cor-
responding quartile as the variation. Statistically sig-
nificant differences for all tests were set at P<0.05. All 
statistical analyses were carried out using Sigma Plot® 
11.0 (Systat Software Inc. San Jose, CA, USA). 
RESULTS
No significant differences were found between all 
experimental groups in regard to body weight or water 
intake across all experimental phases (data not shown).
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Table I shows that, during the first week of alco-
hol intake assessment, there was a significant differ-
ence between the forced alcohol consumption groups 
(ACVEH, ACSDE, and ACSALA) and alcohol-naive groups 
(ANVEH, ANSDE, and ANSALA). However, there was no 
significant difference between days and treatment/
days interaction during the first week. 
We performed a statistical analysis of the 14-day al-
cohol intake. Regarding consumption of the 10% etha-
nol at respective injection days, a significant difference 
was found between groups [F(5,546)=13.06; P<0.001], and 
between days [F(13,546)=4.211; P<0.001]. We found that 
ACVEH, ACSDE, and ACSALA differ significantly from 
ANVEH, ANSDE, and ANSALA from day-1 to day-14. 
Also, groups ACVEH, ACSDE, ANSALA and ACSALA 
showed a greater ethanol intake at days 8 and 9 relative 
to the ANVEH and ANSDE groups. However, there was 
no significant interaction between treatment/injected 
drug/day [F(65,546)=1.055; P=0.367] (Fig. 2A). 
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Table I. Statistical analysis of the first week of alcohol intake assessment.
Treatment Days Treatment/Days















Results of two‑way RM‑ANOVA from days 1 to 7. §P<0.001 difference between 
treatments (ACVEH, ACSDE, and ACSALA vs. ANVEH, ANSDE, and ANSALA). 
(n=8 per group). 
Fig. 2. Alcohol intake (g/kg/day). (A) 10% alcohol intake, (B) 20% alcohol intake, and (C) total alcohol intake. Data are expressed as the mean ± SEM. 
*P<0.05 days 8 and 9 or 8, 9, 10, 11, and 12 vs. days 1, 2, 3, 4, 5, 6, 7, 13, and 14; &P<0.05 ACVEH, ACSDE and ACSALA vs. ANVEH, ANSDE, ANSALA; 
#P<0.05 ANSDE vs. ANVEH and ANSALA; $P<0.05 ACSALA vs. ACVEH, ACSDE. Dotted line represents the daily vehicle or drug injection starting at day‑7 
of assessment. 
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The intake of 20% ethanol was significantly differ-
ent between the ACSDE and ACSALA groups relative 
to the other treatment groups [F(5,546)=12.119; P<0.001]. 
ANSALA, ACSDE, and ACSALA exhibited an increased 
alcohol intake relative to ANVEH, ANSDE, and ACVEH 
from days-8 to day-12 of assessment [F(13,546)=1.780; 
P=0.043]. There was no interaction between treatment/
injected drug/day [F(5,546)=0.442; P=1.00] (Fig. 2B). 
The total alcohol intake (10% and 20%) was signifi-
cant different between the ACSDE and ACSALA groups 
relative to the alcohol-naive groups from day-1 to 
day-14 [F(5,546)=24.986; P<0.001]. Namely, the groups with 
forced alcohol consumption during their juvenile age 
increased their alcohol intake from day-7, i.e., day-1 
of respective injection. Interestingly, between the al-
cohol-naive groups, the ANSALA group significantly 
increased its alcohol consumption relative to the AN-
VEH and ANSDE groups. However, ANSDE group also in-
creased their alcohol intake relative to ANVEH. In ad-
dition, we found a significant difference between days 
8 and 9, the greatest effect after respective vehicle 
or drug injection [F(13,546)=4.742; P=0.01]. There was no 
interaction between treatment/injected drug/day 
[F(5,546)=0.075; P=0.242] (Fig. 2C).
Food consumption between groups before vehicle 
or drug injections was similar. However, there were 
statistically significant differences in the food intake 
between the injected SDE and Sal-A groups relative to 
the injected VEH groups [F(5,546)=10.774; P<0.001]. The 
food intake in the ANSDE and ACSDE groups was signifi-
cantly reduced at days 8 and 9 of measurement (days 2 
and 3 of injection) [F(13,546)=60.761; P<0.001]. A two-way 
RM-ANOVA also revealed a significant interaction be-
tween groups and days [F(65,546)=9.898; P<0.001]. On days 
10, 11, and 12, food intake was significantly decreased 
in the ANSALA and ACSALA groups as compared to the 
other groups (ANVEH, ANSDE, ACVEH, and ACSDE). Par-
ticularly, on day-11, the ANSALA and ACSALA groups 
differed significantly and food intake was further de-
creased in the ANSALA group (Fig. 3).
A significant increase was shown on the dura-
tion of tonic immobility in the injected SDE and Sal-A 
groups (ANSDE, ANSALA, ACSDE and ACSALA) relative 
to the vehicle groups (ANVEH and ACVEH) [H(3)=21.323; 
P<0.001] (Fig. 4).
DISCUSSION
In the present study, we report that the forced treat-
ment of cyclic alcohol intake and withdrawal at two pe-
riods during juvenile age is sufficient to enhance the 
voluntary consumption of alcohol in the experimental 
rats relative to alcohol-naive rats. This data agrees with 
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Fig. 3. Food intake (g/day). Data are expressed as the mean ± SEM. *P<0.05 ANSDE, ANSALA, ACSDE and ACSALA vs. ANVEH and ACVEH. **P<0.05 ANSALA 
and ACSALA vs. ANVEH, ANSDE, ACVEH, and ACSDE; #P<0.05 ANSALA vs. ACSALA. Dotted line represents the daily vehicle or drug injection starting at day‑7 
of assessment.
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the findings shown by Mendoza-Ruiz et al. (2018) who 
provided evidence of same phenomenon. Moreover, it 
has been reported that prolonged exposure to etha-
nol intake can induce a dependence-like state (Walker 
and Koob, 2008). As has been previously hypothesized, 
such a dependence-like state might be modulated by 
the KOP system. Here, we show that exposure to SDE 
increased the alcohol intake in alcohol-naive rats but 
mainly in rats with a history of alcohol consumption. 
Further, our data indicate that Sal-A enhanced alcohol 
intake in rats with, or without, previous alcohol expo-
sure. To our knowledge, this is the first report which 
links the administration of S. divinorum extract to in-
creased alcohol intake. Further, this observation was 
subsequently confirmed in our study through the in-
jection of Sal-A into experimental rats.
In rats previously subjected to forced alcohol con-
sumption during juvenility, the injection of the SDE 
or Sal-A, significantly increased the voluntary alcohol 
intake: 10% ethanol for the first two days after injec-
tion, and both 20% ethanol and total ethanol for the 
first five days of administration. Further, SDE also in-
creased alcohol intake in alcohol-naive rats (ANSDE) at 
the level of the group previously subjected to forced 
alcohol consumption and injected vehicle (ACVEH) but 
solely at 20% and total for the third day and both the 
third and fourth days of administration, respectively. 
At the first day of injection, ACSDE rats drank signifi-
cantly more 20% alcohol than ANVEH group, but not 
more than the ACVEH and ANSDE groups. Furthermore, 
after the daily injection of Sal-A, the compound was 
found to increase alcohol intake: 10%, 20% and total for 
the first days: 1-2, 1-5 and 1-7 days (except the sixth 
day) in rats with, or without, previously forced alcohol 
consumption. 
The present findings are in accordance with data 
reported by Hölter et al. (2000) which demonstrated 
that the stimulation of KOPr with the highly selective 
agonist, CI-977 (enadoline), can increase ethanol in-
take, at least in long-term ethanol-experienced Wistar 
rats. Since KOPr agonists have aversive motivational 
consequences, increased ethanol drinking might be an 
attempt to counteract the aversive effects of this treat-
ment (Hölter et al., 2000). The level of stress, as well as 
a history of brain alcohol exposure, may be important 
determinants of the consequences of KOPr activation/
blockade for alcohol reward and self-administration 
(Hölter et al., 2000). Our data support the hypothesis 
that behaviors associated with withdrawal from etha-
nol are regulated by the KOP system. 
In another study, male Wistar rats with a history 
of ethanol dependence showed a significant decrease 
in open-arm exploration, which can be interpreted as 
immobility, on the elevated plus maze (EPM) after ex-
posure to restraint, indicating an anxiety-like state, 
compared to similarly treated controls, an effect that 
was blocked by a KOPr antagonist nor-BNI (0-20 mg/kg, 
i.p.) (Gillett et al., 2013). In the same study, the highest 
dose of a KOPr agonist U50, 488H decreased open-arm 
exploration and the total number of arm entries in eth-
anol-exposed and control rats; such is in line with the 
present findings. 
Interestingly, the administration of S. divinorum 
at a similar level to its main compound Sal-A pro-
duced a robust conditioned place aversion (CPA) in 
Sprague-Dawley rats (Sufka et al., 2014) similar to oth-
er KOPr agonists such as U50, 488H (Tzschentke, 2007; 
Sufka et al., 2014). CPA might represent a decrease 
in dopamine levels by 30% to 70% at a dose of 1 to 
3.2 mg/kg respectively of Sal-A via i.p. in the caudate 
putamen, but not at nucleus accumbens (NAc) in mice 
(Zhang et al., 2005) which is fully according to a de-
creased in locomotor activity at both concentrations. 
In other studies, Sal-A which was isolated and puri-
fied from S. divinorum plant leaves, dose-dependently 
increased immobility in the FST, an opposite effect to 
that of standard antidepressant drugs. The doses of 
Sal-A which produced these effects in the FST did not 
affect locomotor activity in an open field test, which 
infers a depressive-like effect (Carlezon et al., 2006) 
and not any ataxic or sedative effects. Moreover, Sal-A 
dose dependently elevated intracranial self-stimula-
tion (ICSS) thresholds, an effect similar to that pro-
duced by treatments that cause depressive symptoms 
in humans. Further, Sal-A produced anxiogenic effects 
in rats decreasing time spent in open arms on the EPM 
(Ewald et al., 2017). According to the present results, 
a significantly longer period of immobility occurs af-
ter the administration of SDE or Sal-A in rats. To the 
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Fig.  4. Tonic immobility (s). Data are expressed as the median and the 
interquartile range 25 and 75. *P<0.05 ANSDE, ANSALA, ACSDE and 
ACSALA vs. ANVEH and ACVEH. 
S. div. increases alcohol/anxiety and decreases food intakeActa Neurobiol Exp 2021, 81
best of our knowledge, the present findings are the 
first to show a significant increase in tonic immobil-
ity following the i.p. injection of SDE or Sal-A in rats. 
As a passive defensive behavior, tonic immobility may 
serve to evaluate an anxiety-like state (Vázquez-León 
et al., 2017), and this result fits with the pharmacologic 
profile accepted for the S. divinorum, or its main com-
pound Sal-A, as an agonist of dynorphin/KOPr system 
and as an anxiogenic drug. 
KOPr agonists such as dynorphin and U50, 488H 
have been shown enhanced food intake in rats (Mor-
ley and Levine, 1983). In contrast to our data, we re-
port a reduction in food consumption following the 
administration of SDE – whose effect is attributable 
to its main active principle, Sal-A. The administra-
tion of KOPr agonists in the context of a free-access 
drinking paradigm may involve more general appeti-
tive actions (Wee and Koob, 2010). Additionally, it is 
suggested that the KOP system could affect ingestive 
behaviors mediating palatability, especially in regard 
to a sweet taste (Woolley et al., 2007). Sal-A and its an-
alogues can also evoke different responses in the mod-
ulation of natural reward (Ewald et al., 2017). Howev-
er, in previous studies, Sal-A (0.3, 1.0 mg/kg i.p.) was 
shown to have no significant effects on the intake of 
10% sucrose solution (Morani et al., 2009). Within this 
study, SDE administration produced a significant but 
transient anorexigenic effect with both pre-treatment 
conditions: in the presence and absence of previous-
ly forced alcohol consumption. The period of the de-
creased food intake only lasted two days, probably due 
to the activation of homeostatic mechanisms involved 
in metabolic/energetic balance which would lead to 
the reinstatement of the previous level of food intake. 
In the present study, the concentration of SDE was the 
same every day during the injection period. Perhaps, 
if the concentration of Sal-A from SDE had been grad-
ually increased, the anorexigenic effect would have 
been sustained. The occurrence of significant anorexia 
was observed with the administration of Sal-A during 
the first five days of injection. Interestingly, food con-
sumption returned to the previous range without “re-
bound” after the 2-days for SDE group, and 5-days for 
Sal-A group, respectively. An alternative, but a less 
likely, explanation for the anorexigenic effect of SDE 
and Sal-A is that the boost in ethanol consumption, 
which entailed a lightly greater caloric intake, coin-
cided with the decrease in food consumption, at least 
during the first 2-day of injection. However, the an-
orexigenic effect was observed in the SDE injected 
group, independently of previous alcohol exposure 
and was highlighted as well as prolonged by the Sal-A 
injection. Likely, the caloric value provided by alcohol 
in all experimental groups does not reach significant 
difference. Such calculation is beyond the goals of the 
present study. However, the top level of alcohol in-
take was 2.8 ± 0.7 g/kg/day in the ANSALA, ACSDE and 
ACSALA groups at days 2 and 3 of i.p. injection. 
In a two-week treatment study, minimal histologi-
cal differences were observed after high doses of Sal-A 
when administered by i.p. (Mowry et al., 2003; Grund-
mann et al., 2007). In the present study, injection of 
the SDE or Sal-A was carried out daily for a week. This 
approach shortens the likelihood of toxicity, even at 
the dose used. Nevertheless, to the present, no study 
has exhaustively investigated chronic or acute toxicity 
of the leaf extract of S. divinorum (Grundmann et al., 
2007). In the present study, we suggest an anorexigen-
ic effect for the SDE and its main active component, 
Sal-A. The anorexigenic, dipsogenic for alcohol, and 
anxiogenic effects of SDE or Sal-A, could support, at 
least in part, the thought as to why S. divinorum is con-
sidered a non-addictive drug. Moreover, current data 
is suggestive minimal abuse potential for S. divinorum. 
Previous studies have illustrated this idea by showing 
that Sal-A was able to elevate the thresholds for intra-
cranial stimulation and decreased extracellular dopa-
mine concentrations in the NAc in rats (Carlezon et al., 
2006). Furthermore, reports from human case studies 
have not mentioned any toxic side effects linked to the 
use of S. divinorum as a recreational drug (Grundmann 
et al., 2007). 
Future research is needed to elucidate the role of 
S. divinorum and its main active constituent, Sal-A, in 
the KOP system as well as to better understand the dip-
sogenic, orexigenic, depressive-like and anxiety-like 
behaviors in animals and humans during drug intake.
CONCLUSION
Injection of S. divinorum extract fostered greater al-
cohol intake in Wistar rats, especially in the animals 
with a history of forced ethanol consumption (that 
began at a juvenile age). Injection of Sal-A increased 
alcohol consumption independently of previous alco-
hol exposure. Additionally, there was an anorexigenic 
effect with the administration of SDE or salvinorin A, 
as well as an increase in tonic immobility, suggesting 
an anxiety-like effect.
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